An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies

An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies

IntroductionCytokine release syndrome (CRS) is a potentially severe systemic inflammatory condition triggered by various immunomodulatory therapies, making understanding its pathogenesis critical for improving patient outcomes.Results/MethodsBy combining immunotoxicology and systems biology approach...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexander Mazein, Oxana Lopata, Kristin Reiche, Katherina Sewald, Miriam Alb, Christina Sakellariou, Patricia Gogesch, Hannah Morgan, Vanessa Neuhaus, Nhu-Nguyen Pham, Charline Sommer, Ethan Perkins, Birgit Fogal, Muhammad Shoaib, Reinhard Schneider, Venkata Satagopam, Marek Ostaszewski
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Immunology
Subjects:
systems biology
systems toxicology
immunomodulatory therapies
adverse outcome pathway (AOP)
cytokine release syndrome (CRS)
CAR T cells
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1601670/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1601670/full

Similar Items